# Joaquim Bellmunt

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/joaquim-bellmunt/

## Facts

| Field | Value |
| --- | --- |
| Citations | 67,661 |
| Field | Bladder and Urothelial Cancer Treatments |
| h-index | 107 |
| i10-index | 456 |
| Last Known Institution | Dana-Farber Cancer Institute |
| OpenAlex ID | https://openalex.org/A5074756323 |
| ORCID iD | https://orcid.org/0000-0003-2328-3421 |
| Works | 1,134 |

## Researcher papers

- [Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial](https://scholariq.org/papers/atezolizumab-in-patients-with-locally-advanced-and-metastatic-urothelial/)
- [Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma](https://scholariq.org/papers/pembrolizumab-as-second-line-therapy-for-advanced-urothelial-carcinoma/)
- [Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma](https://scholariq.org/papers/avelumab-maintenance-therapy-for-advanced-or-metastatic-urothelial-carcinoma/)
- [Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors](https://scholariq.org/papers/genomic-correlates-of-response-to-immune-checkpoint-blockade-in-microsatellite/)
- [Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/durvalumab-alone-and-durvalumab-plus-tremelimumab-versus-chemotherapy-in/)
- [EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†](https://scholariq.org/papers/eau-esmo-consensus-statements-on-the-management-of-advanced-and-variant-bladder/)

## Researcher topics

- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Urinary and Genital Oncology Studies](https://scholariq.org/topics/urinary-and-genital-oncology-studies-2/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)

## Researcher university

- [Dana-Farber Cancer Institute](https://scholariq.org/institutions/dana-farber-cancer-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.